The Global Ophthalmic Drugs Market

Ophthalmic Drugs Market – Global Drivers, Restraints, Opportunities, Trends, and Forecast up to 2024

Overview:
Ophthalmic drugs are widely used for the treatment of eye disorders such as glaucoma, conjunctivitis, cataract, dry eyes, diabetic retinopathy, and others. Development of innovative ophthalmic drug delivery methods has aided the drug manufacturers in  developing effective and  advanced therapeutic tactics. American Academy of Ophthalmology has stated that, nearly 11 million individuals in the US are correctly suffering with age-related macular degeneration (AMD), while almost 10% of that population have wet AMD. Such inclinations eye ailments worldwide contribute to the development of the ophthalmic drugs market.

The other significant aspects that help in the improvement the market are high pervasiveness of glaucoma globally and intensification in evolution in the development of combination drugs for the glaucoma.

Additionally, the changing aspects in the demography worldwide are driving the growth of the market. Nevertheless, hazard of side effects related to ophthalmic drugs and loss of patent for blockbuster drugs are hampering the market growth.

Market Analysis:
The “global ophthalmic drugs market” is estimated to witness a CAGR of 6.3% during the forecast period 2018–2024. The global ophthalmic drugs market is analyzed based on indication type and regions.

Regional Analysis:
The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share of the ophthalmic drugs market, followed by Europe, Asia

Pacific, and Rest of the World. North America alone occupies more than 35% of the market, with a significant contribution from the US to the market growth.

Indication Type Analysis: Based on the Indication type, the market is segmented into dry eyes, glaucoma, eye infection/inflammation, retinal disorders, and others. The market is dominated by retinal disorders and is also expected to be the fastest growing segment. However, glaucoma is the second largest segment, owing to the high prevalence of diseases and lack of awareness among the people.

Key Players:
Novartis AG, Pfizer, Allergan Inc., Valeant Pharmaceutical International, Santen Pharmaceutical Co., Ltd., Regeneron Pharmaceutical, Akron Inc. and Johnson & Johnson are the key players in the market. Shire Plc, Daiichi Sankyo, Inc., Bayer AG, F.Hoffmann-La Roche, and Sun Pharmaceuticals are the companies to watch for.

Competitive Analysis:
In future, several blockbuster drugs that have dominated the market, are expected to lose their patents. The patents of successful products accounted for over $6 billion. . The loss of patent is the most important aspect imposing major threat to the leaders in the ophthalmic drugs market., Lupin Pharmaceuticals received US FDA approval on February 2015, for its bimatoprost ophthalmic solution 0.03%, the generic version of Lumigan. This affected the Allergan’s market. Formycon AG, a German biosimilars developing company is currently developing biosimilar for Eylea by Regeneron Pharmaceuticals. Allergan, meanwhile, is under the threat from Akron, which is developing a generic version of Restasis. The release of such product is likely to generate an strong burden on the market players.

Benefits:
The report provides complete details about the usage and adoption rate of ophthalmic drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.